Description

Cisplatin Concentrate for Infusions 1 mg/ml. 100 ml. (100 mg.) Vial №1

Ingredients:

Each ml contains 1 mg of cisplatin. Other ingredients may include sodium chloride, hydrochloric acid, and water for injections.

Dosage:

The dosage is individualized based on the patient’s condition, weight, and overall health. It is typically administered intravenously by a healthcare professional.

Indications:

Cisplatin is used to treat various types of cancer, including testicular, ovarian, bladder, and lung cancers. It works by interfering with the growth of cancer cells.

Contraindications:

Do not use cisplatin if you have a history of allergic reactions to platinum-containing compounds. It is also contraindicated in patients with severe kidney problems.

Directions:

Follow the instructions provided by your healthcare provider. Cisplatin is typically given in a hospital setting due to the need for close monitoring.

Scientific Evidence:

Studies have shown that cisplatin is effective in the treatment of various cancers. Research published in the Journal of Clinical Oncology demonstrated the efficacy of cisplatin in combination therapy for advanced bladder cancer.

Additional Information:

It is important to stay well-hydrated during cisplatin treatment to help protect the kidneys from potential damage. Regular blood tests are often required to monitor kidney function and overall health during treatment.

Cisplatin exerts its pharmacological effects by forming cross-links with DNA, leading to cell death. This mechanism makes it a potent cytotoxic agent against rapidly dividing cancer cells. Additionally, cisplatin has been studied in combination therapies to enhance its effectiveness and reduce resistance development.

Clinical trials have shown that cisplatin, when used in appropriate regimens, can significantly improve patient outcomes and survival rates in various cancer types. Its role in adjuvant and neoadjuvant settings has been well-documented, highlighting its importance in modern oncology treatment protocols.